Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915912 | 0.91 | CA1 (0.40) | TAS1R3TAS1R1TAS1R2CA1PTPN1 | |
| SCHEMBL12018037 | 0.79 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30186582 | 0.78 | KMT2A (0.33) | — | |
| SCHEMBL24917037 | 0.78 | KMT2A (0.39) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19105012 | 0.76 | KDM4E (0.37) | TAS1R3TAS1R1TAS1R2CA1PTPN1 | |
| SCHEMBL24916959 | 0.75 | MEN1 (0.31) | — | |
| SCHEMBL8003191 | 0.75 | KMT2A (0.41) | CA1 | |
| SCHEMBL19117101 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL24629347 | 0.74 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21533163 | 0.73 | HTR2C (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862682-B2 | Functionalized pegylated cyanine compounds, pharmaceutical compositions, and methods of use thereof | BroadPharm (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170197916-A1 | FUNCTIONALIZED PEGYLATED CYANINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | BroadPharm (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197916-A1 | FUNCTIONALIZED PEGYLATED CYANINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ABL1, EGFR, ALB | TAS1R3 2109/4885TAS1R1 1920/4885TAS1R2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.